The talazoparib treatment regimen demonstrated a significant improvement in rPFS vs placebo plus enzalutamide, exceeding the pre-specified target hazard ratio of 0.63. Topline data were announced from ...
New data suggest that olaparib without ADT could be a reasonable treatment strategy in selected patients with high-risk prostate cancer that recurs after radical prostatectomy. Olaparib monotherapy ...
Trends in local therapy utilization and survival of patients with de-novo metastatic prostate cancer treated by hormone therapy with or without systemic therapy intensification with chemotherapy. This ...
Effect of combined treatment with sipuleucel-T and IL-15 on tumor control, tumor-infiltrating immune effectors, and key mediators of immunoresistance in a preclinical prostate cancer model. The ...
Akeega reduced radiographic progression or death risk by 37% in mCSPC patients with HRR gene alterations. Significant reduction in symptomatic progression risk by 50% and a trend towards improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results